FOLH1 and posterior cortical atrophy: Among the emerging indications for PSMA PET is the evaluation of patients with biochemical recurrence (BCR) after initial curative-intent therapy [4] and the identification of men with oligometastatic PCa (typically being defined as ≤5 sites of distant disease) [5].